milrinone has been researched along with sotalol in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Horowitz, JD; Ritchie, RH; Zhang, YI | 1 |
Bristow, MR; Eki, Y; Focaccio, A; Krall, J; Movsesian, M; Peeters, G; Roden, R | 1 |
1 review(s) available for milrinone and sotalol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for milrinone and sotalol
Article | Year |
---|---|
Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiac Complexes, Premature; Cardiotonic Agents; Female; Humans; Injections, Intravenous; Male; Metoprolol; Middle Aged; Milrinone; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Phosphodiesterase Inhibitors; Pyridones; Sotalol; Ventricular Function, Left | 1995 |
4 other study(ies) available for milrinone and sotalol
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mechanism of action of OPC-8490 in human ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Action Potentials; Adult; Azetidines; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Enoximone; Heart; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Ion Channels; Middle Aged; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Piperazines; Pyridones; Quinolones; Sotalol; Ventricular Function; Veratridine | 1996 |